GORTEC Announces New Trial Success for Head and Neck Cancer Treatment
GORTEC, known as Head and Neck Radiation Oncology Group, today announced that the randomized Phase 3 NIVOPOSTOP GORTEC 2018-01 trial evaluating nivolumab, Bristol Myers Squibb's anti-PD-1 therapy, as ...
Should Bristol-Myers Squibb Company (NYSE:BMY) Be In Your Early Retirement Portfolio?
We recently compiled a list of the Early Retirement Portfolio: 10 Stocks to Live Off Dividends. In this article, we are going ...
bernama9h
US SENATOR VOWS TO BLOCK ARMS SALES TO ISRAEL
US Senator Bernie Sanders pledged Monday to do everything he can to block arms sales to Israel, Anadolu Agency reported. "The US must not send mo ...
Bristol Myers to report Q4 IPRD/licensing expense of $18M
Bristol Myers Squibb (NYSE:BMY) said it expects to report a Q4 net expense of $18M related to acquired IPRD and licensing ...
Peninsula biotech to lay off 40% of workforce as it restructures
Cancer-focused CytomX Therapeutics Inc. will lay off 40% of its workforce — about 50 employees — to help extend its cash into ...
precisionmedicineonline20h
I-Mab Streamlines Operations, Focuses Pipeline on CLDN18.2-Directed Therapy
The firm is shifting its resources to fund and expand its Phase I clinical trial of givastomig in CLDN18.2-expressing advanced solid tumor patients.